Seattle Genetics (SGEN) Reports Lintuzumab Phase IIb Did Not Meet Primary Endpoint; To Discontinue Development
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that their phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
